The National Cancer Institute awarded a $183,044 Project Grant (CFDA 93.398 - Cancer Research Manpower) to the Regents of the University of Michigan, Office of Research and Sponsored Projects Division, to conduct research focused on "Resolving Viral Oncoprotein Control of Terminal Cell Fates to Limit Epstein-Barr Virus-Driven Lymphoproliferation". This 3-year research project aims to enhance the understanding of how the Epstein-Barr virus (EBV) oncoproteins EBNA3A and EBNA3C interact with the cellular regulator EZH2 to promote proliferation of EBV-infected B cells and drive lymphoma development. The research will apply single-cell techniques to define the mechanisms by which this viral-cellular axis controls B cell fate decisions, with the goal of identifying vulnerabilities that could be targeted for improved treatment of EBV-associated lymphomas.
Generated 3/4/25, 5:26 AM